| # | Title | Journal | Year | Citations |
|---|
| 1 | Metastatic Behavior of Breast Cancer Subtypes | Journal of Clinical Oncology | 2010 | 1,718 |
| 2 | The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP | Blood | 2007 | 1,193 |
| 3 | Ki67 in breast cancer: prognostic and predictive potential | Lancet Oncology, The | 2010 | 923 |
| 4 | Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity | Blood | 2015 | 445 |
| 5 | Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma | Journal of Clinical Oncology | 2001 | 406 |
| 6 | The impact of new chemotherapeutic and hormone agents on survival in a population‐based cohort of women with metastatic breast cancer | Cancer | 2007 | 399 |
| 7 | Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study | Lancet Oncology, The | 2016 | 373 |
| 8 | Lessons learned from measuring health-related quality of life in oncology. | Journal of Clinical Oncology | 1994 | 358 |
| 9 | Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's Lymphoma | Journal of Clinical Oncology | 2008 | 333 |
| 10 | Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification | Annals of Oncology | 2004 | 314 |
| 11 | BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma | Cancer Discovery | 2019 | 278 |
| 12 | Pathogenesis of follicular lymphoma | Journal of Clinical Investigation | 2012 | 264 |
| 13 | Oblimersen Bcl-2 Antisense: Facilitating Apoptosis in Anticancer Treatment | Oligonucleotides | 2002 | 241 |
| 14 | Epidermal growth factor receptor: a promising target in solid tumours | Cancer Treatment Reviews | 2004 | 228 |
| 15 | Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial | Lancet Oncology, The | 2019 | 227 |
| 16 | Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2 | Gynecologic Oncology | 2017 | 222 |
| 17 | Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models | British Journal of Cancer | 1995 | 214 |
| 18 | Expression of the Hypoxia-Inducible and Tumor-Associated Carbonic Anhydrases in Ductal Carcinoma in Situ of the Breast | American Journal of Pathology | 2001 | 212 |
| 19 | Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles | BBA - Biomembranes | 1997 | 185 |
| 20 | Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy | Annals of Oncology | 2010 | 182 |
| 21 | Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial | Annals of Oncology | 2020 | 160 |
| 22 | The biology and management of systemic anaplastic large cell lymphoma | Blood | 2015 | 157 |
| 23 | Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study | Blood | 2018 | 151 |
| 24 | Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. | Journal of Clinical Oncology | 1997 | 150 |
| 25 | Formation of transition metal–doxorubicin complexes inside liposomes | Biochimica Et Biophysica Acta - Biomembranes | 2002 | 150 |
| 26 | Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18) | Genes Chromosomes and Cancer | 2001 | 142 |
| 27 | Basal Breast Cancer Molecular Subtype Predicts for Lower Incidence of Axillary Lymph Node Metastases in Primary Breast Cancer | Clinical Breast Cancer | 2008 | 135 |
| 28 | BCL2 mutations in diffuse large B-cell lymphoma | Leukemia | 2012 | 135 |
| 29 | Carbonic anhydrase XII is a marker of good prognosis in invasive breast carcinoma | British Journal of Cancer | 2003 | 129 |
| 30 | Anaplastic large cell lymphoma, ALK-negative | Critical Reviews in Oncology/Hematology | 2013 | 129 |
| 31 | Ten-Year Outcomes in a Population-Based Cohort of Node-Negative, Lymphatic, and Vascular Invasion–Negative Early Breast Cancers Without Adjuvant Systemic Therapies | Journal of Clinical Oncology | 2004 | 127 |
| 32 | Formation of Novel Hydrophobic Complexes between Cationic Lipids and Plasmid DNA | Biochemistry | 1995 | 124 |
| 33 | Asian Ethnicity–Related Differences in Gastric Cancer Presentation and Outcome Among Patients Treated at a Canadian Cancer Center | Journal of Clinical Oncology | 2003 | 124 |
| 34 | NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma | Clinical Cancer Research | 2019 | 121 |
| 35 | Altered Gene Expression along the Glycolysis–Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer | Clinical Cancer Research | 2020 | 121 |
| 36 | Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988 | Blood | 1991 | 119 |
| 37 | Adjuvant chemotherapy use and outcomes of patients with high‐risk versus low‐risk stage II colon cancer | Cancer | 2015 | 118 |
| 38 | Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes | Breast Cancer Research and Treatment | 2012 | 117 |
| 39 | Cationic Lipid Binding to DNA: Characterization of Complex Formation† | Biochemistry | 1996 | 115 |
| 40 | Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. | Journal of Clinical Oncology | 1991 | 114 |
| 41 | Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas | Genes Chromosomes and Cancer | 2004 | 114 |
| 42 | Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma | Blood | 2014 | 110 |
| 43 | Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies | Clinical Cancer Research | 2021 | 110 |
| 44 | Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes | Breast Cancer Research | 2008 | 107 |
| 45 | Physician preferences and attitudes regarding different models of cancer survivorship care: a comparison of primary care providers and oncologists | Journal of Cancer Survivorship | 2013 | 105 |
| 46 | Cytogenetic abnormalities and clinical correlations in peripheral T‐cell lymphoma | British Journal of Haematology | 2008 | 100 |
| 47 | SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2′deoxycytidine to increase SPARC expression and improve therapy response | British Journal of Cancer | 2008 | 100 |
| 48 | Brief Chemotherapy and Involved-Region Irradiation for Limited-Stage Diffuse Large-Cell Lymphoma: An 18-Year Experience From the British Columbia Cancer Agency | Journal of Clinical Oncology | 2002 | 99 |
| 49 | Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting | Blood | 2007 | 98 |
| 50 | Anaplastic large cell lymphoma, ALK-positive | Critical Reviews in Oncology/Hematology | 2012 | 98 |
